Filing Details

Accession Number:
0001209191-23-001932
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-05 17:00:59
Reporting Period:
2023-01-03
Accepted Time:
2023-01-05 17:00:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1706431 Vir Biotechnology Inc. VIR () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1661908 Elliott Charles Sigal C/O Vir Biotechnology, Inc.
499 Illinois Street, Suite 500
San Francisco CA 94158
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-01-03 2,500 $25.60 2,500 No 4 P Indirect By Sigal Family Investments, LLC
Common Stock Acquisiton 2023-01-04 2,500 $25.25 5,000 No 4 P Indirect By Sigal Family Investments, LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By Sigal Family Investments, LLC
No 4 P Indirect By Sigal Family Investments, LLC
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 9,779 Direct
Footnotes
  1. The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Sigal Family Investments, LLC on October 21, 2022, of which the reporting person is the manager.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.41 to $25.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
  3. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
  4. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.08 to $25.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.